プロテオパチーとは？ わかりやすく解説

Weblio 辞書 > 辞書・百科事典 > 百科事典 > プロテオパチーの意味・解説 
ウィキペディア
索引トップ ランキング カテゴリー
ウィキペディアウィキペディア

プロテオパチー

出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2024/04/08 10:12 UTC 版)

医学では、プロテオパチー (proteopathy; プロテオパシーとも) ([proʊtiːˈɒpəθiː]; Proteo- [pref. protein]; -pathy [suff. disease]; proteopathies pl.; proteopathic adj) は、特定のタンパク質が構造的に異常になり、体の細胞、組織、臓器の機能を破壊する疾患のクラスを指す[1][2]。多くの場合、タンパク質は正常な構成にフォールディング (折り畳み) できない。このミスフォールディング (誤った折り畳み) 状態では、タンパク質は何らかの方法で毒性になるか (毒性機能獲得（英語版）)、または通常の機能を失う可能性がある[3]。


参考文献
  1. ^ Walker LC, LeVine H (2000). “The cerebral proteopathies”. Neurobiology of Aging 21 (4): 559–61. doi:10.1016/S0197-4580(00)00160-3. PMID 10924770. 
  2. ^ a b Walker LC, LeVine H (2000). “The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly”. Molecular Neurobiology 21 (1–2): 83–95. doi:10.1385/MN:21:1-2:083. PMID 11327151. 
  3. ^ Luheshi LM, Crowther DC, Dobson CM (February 2008). “Protein misfolding and disease: from the test tube to the organism”. Current Opinion in Chemical Biology 12 (1): 25–31. doi:10.1016/j.cbpa.2008.02.011. PMID 18295611. 
  4. ^ Chiti F, Dobson CM (2006). “Protein misfolding, functional amyloid, and human disease”. Annual Review of Biochemistry 75 (1): 333–66. doi:10.1146/annurev.biochem.75.101304.123901. PMID 16756495. 
  5. ^ Carrell RW, Lomas DA (July 1997). “Conformational disease”. Lancet 350 (9071): 134–8. doi:10.1016/S0140-6736(97)02073-4. PMID 9228977. 
  6. ^ Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD (September 2007). “A primer of amyloid nomenclature”. Amyloid 14 (3): 179–83. doi:10.1080/13506120701460923. PMID 17701465. 
  7. ^ Westermark GT, Fändrich M, Lundmark K, Westermark P (January 2018). “Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission”. Cold Spring Harbor Perspectives in Medicine 8 (1): a024323. doi:10.1101/cshperspect.a024323. PMID 28108533. 
  8. ^ Prusiner SB (2013). “Biology and genetics of prions causing neurodegeneration”. Annual Review of Genetics 47: 601–23. doi:10.1146/annurev-genet-110711-155524. PMC 4010318. PMID 24274755. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010318/. 
  9. ^ Walker LC, LeVine H (2000). “The cerebral proteopathies”. Neurobiology of Aging 21 (4): 559–61. doi:10.1016/S0197-4580(00)00160-3. PMID 10924770. 
  10. ^ a b Sipe JD, Cohen AS (June 2000). “Review: history of the amyloid fibril”. Journal of Structural Biology 130 (2–3): 88–98. doi:10.1006/jsbi.2000.4221. PMID 10940217. 
  11. ^ Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J (July 1998). “Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease”. Journal of Neuropathology and Experimental Neurology 57 (7): 674–83. doi:10.1097/00005072-199807000-00004. PMID 9690671. 
  12. ^ Glabe CG (April 2006). “Common mechanisms of amyloid oligomer pathogenesis in degenerative disease”. Neurobiology of Aging 27 (4): 570–5. doi:10.1016/j.neurobiolaging.2005.04.017. PMID 16481071. 
  13. ^ Gadad BS, Britton GB, Rao KS (2011). “Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide”. Journal of Alzheimer's Disease 24 Suppl 2: 223–32. doi:10.3233/JAD-2011-110182. PMID 21460436. 
  14. ^ a b c Carrell RW, Lomas DA (July 1997). “Conformational disease”. Lancet 350 (9071): 134–8. doi:10.1016/S0140-6736(97)02073-4. PMID 9228977. 
  15. ^ Luheshi LM, Crowther DC, Dobson CM (February 2008). “Protein misfolding and disease: from the test tube to the organism”. Current Opinion in Chemical Biology 12 (1): 25–31. doi:10.1016/j.cbpa.2008.02.011. PMID 18295611. 
  16. ^ Ito D, Suzuki N (October 2011). “Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS”. Neurology 77 (17): 1636–43. doi:10.1212/WNL.0b013e3182343365. PMC 3198978. PMID 21956718. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198978/. 
  17. ^ Wolozin B, Apicco D (2015). “RNA binding proteins and the genesis of neurodegenerative diseases”. Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology 822: 11–5. doi:10.1007/978-3-319-08927-0_3. ISBN 978-3-319-08926-3. PMC 4694570. PMID 25416971. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694570/. 
  18. ^ a b c Dobson CM (September 1999). “Protein misfolding, evolution and disease”. Trends in Biochemical Sciences 24 (9): 329–32. doi:10.1016/S0968-0004(99)01445-0. PMID 10470028. 
  19. ^ Jucker M, Walker LC (September 2013). “Self-propagation of pathogenic protein aggregates in neurodegenerative diseases”. Nature 501 (7465): 45–51. doi:10.1038/nature12481. PMC 3963807. PMID 24005412. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963807/. 
  20. ^ Selkoe DJ (December 2003). “Folding proteins in fatal ways”. Nature 426 (6968): 900–4. doi:10.1038/nature02264. PMID 14685251. 
  21. ^ Eisenberg D, Jucker M (March 2012). “The amyloid state of proteins in human diseases”. Cell 148 (6): 1188–203. doi:10.1016/j.cell.2012.02.022. PMC 3353745. PMID 22424229. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353745/. 
  22. ^ Walker LC (November 2016). “Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases”. Annual Review of Genetics 50: 329–346. doi:10.1146/annurev-genet-120215-034943. PMC 6690197. PMID 27893962. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690197/. 
  23. ^ Collinge J, Clarke AR (November 2007). “A general model of prion strains and their pathogenicity”. Science 318 (5852): 930–6. doi:10.1126/science.1138718. PMID 17991853. 
  24. ^ Colby DW, Prusiner SB (September 2011). “De novo generation of prion strains”. Nature Reviews. Microbiology 9 (11): 771–7. doi:10.1038/nrmicro2650. PMC 3924856. PMID 21947062. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924856/. 
  25. ^ a b Walker LC, LeVine H (2000). “The cerebral proteopathies”. Neurobiology of Aging 21 (4): 559–61. doi:10.1016/S0197-4580(00)00160-3. PMID 10924770. 
  26. ^ Carrell RW, Lomas DA (July 1997). “Conformational disease”. Lancet 350 (9071): 134–8. doi:10.1016/S0140-6736(97)02073-4. PMID 9228977. 
  27. ^ Dobson CM (September 1999). “Protein misfolding, evolution and disease”. Trends in Biochemical Sciences 24 (9): 329–32. doi:10.1016/S0968-0004(99)01445-0. PMID 10470028. 
  28. ^ DeKosky ST, Ikonomovic MD, Gandy S (September 2010). “Traumatic brain injury--football, warfare, and long-term effects”. The New England Journal of Medicine 363 (14): 1293–6. doi:10.1056/NEJMp1007051. PMID 20879875. 
  29. ^ McKee AC, Stein TD, Kiernan PT, Alvarez VE (May 2015). “The neuropathology of chronic traumatic encephalopathy”. Brain Pathology 25 (3): 350–64. doi:10.1111/bpa.12248. PMC 4526170. PMID 25904048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526170/. 
  30. ^ Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (May 2012). “Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature”. Journal of Neuropathology and Experimental Neurology 71 (5): 362–81. doi:10.1097/NEN.0b013e31825018f7. PMC 3560290. PMID 22487856. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560290/. 
  31. ^ Mrak RE, Griffin WS (2007). “Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease”. Neuropsychiatric Disease and Treatment 3 (5): 619–25. PMC 2656298. PMID 19300591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656298/. 
  32. ^ Douglas PM, Summers DW, Cyr DM (2009). “Molecular chaperones antagonize proteotoxicity by differentially modulating protein aggregation pathways”. Prion 3 (2): 51–8. doi:10.4161/pri.3.2.8587. PMC 2712599. PMID 19421006. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712599/. 
  33. ^ Brehme M, Voisine C, Rolland T, Wachi S, Soper JH, Zhu Y, Orton K, Villella A, Garza D, Vidal M, Ge H, Morimoto RI (November 2014). “A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease”. Cell Reports 9 (3): 1135–50. doi:10.1016/j.celrep.2014.09.042. PMC 4255334. PMID 25437566. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255334/. 
  34. ^ Brehme M, Voisine C (August 2016). “Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity”. Disease Models & Mechanisms 9 (8): 823–38. doi:10.1242/dmm.024703. PMC 5007983. PMID 27491084. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007983/. 
  35. ^ Hardy J (August 2005). “Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration”. Biochemical Society Transactions 33 (Pt 4): 578–81. doi:10.1042/BST0330578. PMID 16042548. 
  36. ^ a b Walker LC, Levine H, Mattson MP, Jucker M (August 2006). “Inducible proteopathies”. Trends in Neurosciences 29 (8): 438–43. doi:10.1016/j.tins.2006.06.010. PMID 16806508. 
  37. ^ Prusiner SB (May 2001). “Shattuck lecture--neurodegenerative diseases and prions”. The New England Journal of Medicine 344 (20): 1516–26. doi:10.1056/NEJM200105173442006. PMID 11357156. 
  38. ^ Zou WQ, Gambetti P (April 2005). “From microbes to prions the final proof of the prion hypothesis”. Cell 121 (2): 155–7. doi:10.1016/j.cell.2005.04.002. PMID 15851020. 
  39. ^ Ma J (2012). “The role of cofactors in prion propagation and infectivity”. PLoS Pathogens 8 (4): e1002589. doi:10.1371/journal.ppat.1002589. PMC 3325206. PMID 22511864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325206/. 
  40. ^ Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (September 2006). “Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host”. Science 313 (5794): 1781–4. doi:10.1126/science.1131864. PMID 16990547. 
  41. ^ Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (July 2009). “Transmission and spreading of tauopathy in transgenic mouse brain”. Nature Cell Biology 11 (7): 909–13. doi:10.1038/ncb1901. PMC 2726961. PMID 19503072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726961/. 
  42. ^ Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ (August 2009). “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein”. Proceedings of the National Academy of Sciences of the United States of America 106 (31): 13010–5. doi:10.1073/pnas.0903691106. PMC 2722313. PMID 19651612. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722313/. 
  43. ^ Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P (February 2011). “α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells”. The Journal of Clinical Investigation 121 (2): 715–25. doi:10.1172/JCI43366. PMC 3026723. PMID 21245577. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026723/. 
  44. ^ Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (May 2008). “Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease”. Nature Medicine 14 (5): 504–6. doi:10.1038/nm1747. PMID 18391962. 
  45. ^ Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ (September 2011). “Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat”. Neurobiology of Disease 43 (3): 552–7. doi:10.1016/j.nbd.2011.05.001. PMC 3430516. PMID 21600984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430516/. 
  46. ^ Münch C, O'Brien J, Bertolotti A (March 2011). “Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells”. Proceedings of the National Academy of Sciences of the United States of America 108 (9): 3548–53. doi:10.1073/pnas.1017275108. PMC 3048161. PMID 21321227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048161/. 
  47. ^ Chia R, Tattum MH, Jones S, Collinge J, Fisher EM, Jackson GS (May 2010). Feany, Mel B.. ed. “Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis”. PLOS One 5 (5): e10627. doi:10.1371/journal.pone.0010627. PMC 2869360. PMID 20498711. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869360/. 
  48. ^ Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR (February 2009). “Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates”. Nature Cell Biology 11 (2): 219–25. doi:10.1038/ncb1830. PMC 2757079. PMID 19151706. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757079/. 
  49. ^ Pearce MM, Kopito RR (February 2018). “Prion-Like Characteristics of Polyglutamine-Containing Proteins”. Cold Spring Harbor Perspectives in Medicine 8 (2): a024257. doi:10.1101/cshperspect.a024257. PMC 5793740. PMID 28096245. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793740/. 
  50. ^ Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N (May 2011). “A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions”. The Journal of Biological Chemistry 286 (21): 18664–72. doi:10.1074/jbc.M111.231209. PMC 3099683. PMID 21454603. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099683/. 
  51. ^ Lundmark K, Westermark GT, Olsén A, Westermark P (April 2005). “Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism”. Proceedings of the National Academy of Sciences of the United States of America 102 (17): 6098–102. doi:10.1073/pnas.0501814102. PMC 1087940. PMID 15829582. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087940/. 
  52. ^ Fu X, Korenaga T, Fu L, Xing Y, Guo Z, Matsushita T, Hosokawa M, Naiki H, Baba S, Kawata Y, Ikeda S, Ishihara T, Mori M, Higuchi K (April 2004). “Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils”. FEBS Letters 563 (1–3): 179–84. doi:10.1016/S0014-5793(04)00295-9. PMID 15063745. 
  53. ^ Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M (December 2007). “Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice”. The American Journal of Pathology 171 (6): 2012–20. doi:10.2353/ajpath.2007.070403. PMC 2111123. PMID 18055549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2111123/. 
  54. ^ Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C (March 2010). “Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases”. The Journal of Neuroscience 30 (13): 4528–35. doi:10.1523/JNEUROSCI.5924-09.2010. PMC 2859074. PMID 20357103. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859074/. 
  55. ^ Jucker M, Walker LC (September 2013). “Self-propagation of pathogenic protein aggregates in neurodegenerative diseases”. Nature 501 (7465): 45–51. doi:10.1038/nature12481. PMC 3963807. PMID 24005412. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963807/. 
  56. ^ a b c d Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (September 2003). “Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view”. Journal of Neuropathology and Experimental Neurology 62 (9): 885–98. doi:10.1093/jnen/62.9.885. PMID 14533778. 
  57. ^ Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (August 2007). “Targeting amyloid-beta in glaucoma treatment”. Proceedings of the National Academy of Sciences of the United States of America 104 (33): 13444–9. doi:10.1073/pnas.0703707104. PMC 1940230. PMID 17684098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940230/. 
  58. ^ Prusiner, SB (2004). Prion Biology and Diseases (2 ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. ISBN 0-87969-693-1 
  59. ^ Goedert M, Spillantini MG, Del Tredici K, Braak H (January 2013). “100 years of Lewy pathology”. Nature Reviews. Neurology 9 (1): 13–24. doi:10.1038/nrneurol.2012.242. PMID 23183883. 
  60. ^ Clavaguera F, Hench J, Goedert M, Tolnay M (February 2015). “Invited review: Prion-like transmission and spreading of tau pathology”. Neuropathology and Applied Neurobiology 41 (1): 47–58. doi:10.1111/nan.12197. PMID 25399729. 
  61. ^ a b Mann DM, Snowden JS (November 2017). “Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype”. Brain Pathology 27 (6): 723–736. doi:10.1111/bpa.12486. PMID 28100023. 
  62. ^ Grad LI, Fernando SM, Cashman NR (May 2015). “From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis”. Neurobiology of Disease 77: 257–65. doi:10.1016/j.nbd.2015.02.009. PMID 25701498. 
  63. ^ Ludolph AC, Brettschneider J, Weishaupt JH (October 2012). “Amyotrophic lateral sclerosis”. Current Opinion in Neurology 25 (5): 530–5. doi:10.1097/WCO.0b013e328356d328. PMID 22918486. 
  64. ^ Orr HT, Zoghbi HY (July 2007). “Trinucleotide repeat disorders”. Annual Review of Neuroscience 30 (1): 575–621. doi:10.1146/annurev.neuro.29.051605.113042. PMID 17417937. 
  65. ^ Almeida B, Fernandes S, Abreu IA, Macedo-Ribeiro S (2013). “Trinucleotide repeats: a structural perspective”. Frontiers in Neurology 4: 76. doi:10.3389/fneur.2013.00076. PMC 3687200. PMID 23801983. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687200/. 
  66. ^ Spinner NB (March 2000). “CADASIL: Notch signaling defect or protein accumulation problem?”. The Journal of Clinical Investigation 105 (5): 561–2. doi:10.1172/JCI9511. PMC 292459. PMID 10712425. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC292459/. 
  67. ^ Quinlan RA, Brenner M, Goldman JE, Messing A (June 2007). “GFAP and its role in Alexander disease”. Experimental Cell Research 313 (10): 2077–87. doi:10.1016/j.yexcr.2007.04.004. PMC 2702672. PMID 17498694. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702672/. 
  68. ^ Ito D, Suzuki N (January 2009). “Seipinopathy: a novel endoplasmic reticulum stress-associated disease”. Brain 132 (Pt 1): 8–15. doi:10.1093/brain/awn216. PMID 18790819. 
  69. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P (December 2016). “Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines”. Amyloid 23 (4): 209–213. doi:10.1080/13506129.2016.1257986. PMID 27884064. 
  70. ^ Lomas DA, Carrell RW (October 2002). “Serpinopathies and the conformational dementias”. Nature Reviews Genetics 3 (10): 759–68. doi:10.1038/nrg907. PMID 12360234. 
  71. ^ Mukherjee A, Soto C (May 2017). “Prion-Like Protein Aggregates and Type 2 Diabetes”. Cold Spring Harbor Perspectives in Medicine 7 (5): a024315. doi:10.1101/cshperspect.a024315. PMC 5411686. PMID 28159831. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411686/. 
  72. ^ Askanas V, Engel WK (January 2006). “Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition”. Neurology 66 (2 Suppl 1): S39-48. doi:10.1212/01.wnl.0000192128.13875.1e. PMID 16432144. 
  73. ^ Ecroyd H, Carver JA (January 2009). “Crystallin proteins and amyloid fibrils”. Cellular and Molecular Life Sciences 66 (1): 62–81. doi:10.1007/s00018-008-8327-4. PMID 18810322. 
  74. ^ Surguchev A, Surguchov A (January 2010). “Conformational diseases: looking into the eyes”. Brain Research Bulletin 81 (1): 12–24. doi:10.1016/j.brainresbull.2009.09.015. PMID 19808079. 
  75. ^ Huilgol SC, Ramnarain N, Carrington P, Leigh IM, Black MM (May 1998). “Cytokeratins in primary cutaneous amyloidosis”. The Australasian Journal of Dermatology 39 (2): 81–5. doi:10.1111/j.1440-0960.1998.tb01253.x. PMID 9611375. 
  76. ^ Janig E, Stumptner C, Fuchsbichler A, Denk H, Zatloukal K (March 2005). “Interaction of stress proteins with misfolded keratins”. European Journal of Cell Biology 84 (2–3): 329–39. doi:10.1016/j.ejcb.2004.12.018. PMID 15819411. 
  77. ^ D'Souza A, Theis JD, Vrana JA, Dogan A (June 2014). “Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration”. Amyloid 21 (2): 71–5. doi:10.3109/13506129.2013.876984. PMC 4021035. PMID 24446896. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021035/. 
  78. ^ Meng X, Clews J, Kargas V, Wang X, Ford RC (January 2017). “The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability”. Cellular and Molecular Life Sciences 74 (1): 23–38. doi:10.1007/s00018-016-2386-8. PMC 5209436. PMID 27734094. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209436/. 
  79. ^ Stuart MJ, Nagel RL (2004). “Sickle-cell disease”. Lancet 364 (9442): 1343–60. doi:10.1016/S0140-6736(04)17192-4. PMID 15474138. 
  80. ^ a b c Pepys MB (2006). “Amyloidosis”. Annu Rev Med 57: 223-241. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147. 
  81. ^ a b Holtzman DM, Morris JC, Goate AM (2011). “Alzheimer's disease: the challenge of the second century”. Sci Transl Med 3 (77): 77sr1. doi:10.1126/scitranslmed.3002369. PMC 3130546. PMID 21471435. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130546/. 
  82. ^ Pepys MB (2001). “Pathogenesis, diagnosis and treatment of systemic amyloidosis”. Phil Trans R Soc Lond B 356: 203-211. doi:10.1098/rstb.2000.0766. PMC 1088426. PMID 11260801. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088426/. 
  83. ^ Walker LC, LeVine H 3rd (2002). “Proteopathy: the next therapeutic frontier?”. Curr Opin Investig Drugs 3 (5): 782–7. PMID 12090553. 
  84. ^ Braczynski AK, Schulz JB, Bach JP (2017). “Vaccination strategies in tauopathies and synucleinopathies”. J Neurochem 143 (5): 467-488. doi:10.1111/jnc.14207. PMID 28869766. 
  85. ^ Klein WL (2013). “Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?”. J Alzheimers Dis 33 (Suppl 1): S49-65. doi:10.3233/JAD-2012-129039. PMID 22785404. 
  86. ^ Badar T, D'Souza A, Hari P (2018). “Recent advances in understanding and treating immunoglobulin light chain amyloidosis”. F1000Res 7: 1348. doi:10.12688/f1000research.15353.1. PMC 6117860. PMID 30228867. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117860/. 
  87. ^ Carvalho A, Rocha A, Lobato L (2015). “Liver transplantation in transthyretin amyloidosis: issues and challenges”. Liver Transpl 21 (3): 282-292. doi:10.1002/lt.24058. PMID 25482846. 
  88. ^ Suhr OB, Herlenius G, Friman S, Ericzon BG (2000). “Liver transplantation for hereditary transthyretin amyloidosis”. Liver Transpl 6 (3): 263-276. doi:10.1053/lv.2000.6145. PMID 10827225. 
  89. ^ Suhr OB, Larsson M, Ericzon BG, Wilczek HE et al (2016). “Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry”. Transplantation 100 (2): 373-381. doi:10.1097/TP.0000000000001021. PMC 4732012. PMID 26656838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732012/. 
  90. ^ Coelho T et al (2016). “Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis”. Neurol Ther 5 (1): 1-25. doi:10.1007/s40120-016-0040-x. PMC 4919130. PMID 26894299. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919130/. 
  91. ^ Suhr OB, Larsson M, Ericzon BG, Wilczek HE et al (2016). “Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry”. Transplantation 100 (2): 373-381. doi:10.1097/TP.0000000000001021. PMC 4732012. PMID 26656838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732012/. 
  92. ^ a b Badar T, D'Souza A, Hari P (2018). “Recent advances in understanding and treating immunoglobulin light chain amyloidosis”. F1000Res 7: 1348. doi:10.12688/f1000research.15353.1. PMC 6117860. PMID 30228867. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117860/. 
  93. ^ Yu D et al (2012). “Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression”. Cell 150 (5): 895-908. doi:10.1016/j.cell.2012.08.002. PMC 3444165. PMID 22939619. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444165/. 
  94. ^ Nuvolone M, Merlini G (2017). “Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis”. Expert Opin Ther Targets 21 (12): 1095-1110. doi:10.1080/14728222.2017.1398235. PMID 29076382. 
  95. ^ Joseph NS, Kaufman JL (2018). “Novel Approaches for the Management of AL Amyloidosis”. Curr Hematol Malig Rep 13 (3): 212-219. doi:10.1007/s11899-018-0450-1. PMID 29951831. 

[続きの解説]

「プロテオパチー」の続きの解説一覧

急上昇のことば

うかんむり
オリンピックのサッカー競技
クリムゾン・タイド
叢雲
切り出す
英和和英テキスト翻訳>> Weblio翻訳
英語⇒日本語日本語⇒英語
  
  •  プロテオパチーのページへのリンク

辞書ショートカット

カテゴリ一覧

全て

＋ ビジネス

＋ 業界用語

＋ コンピュータ

＋ 電車

＋ 自動車・バイク

＋ 船

＋ 工学

＋ 建築・不動産

＋ 学問

＋ 文化

＋ 生活

＋ ヘルスケア

＋ 趣味

＋ スポーツ

＋ 生物

＋ 食品

＋ 人名

＋ 方言

＋ 辞書・百科事典

すべての辞書の索引

あいうえお
かきくけこ
さしすせそ
たちつてと
なにぬねの
はひふへほ
まみむめも
やゆよ
らりるれろ
わをん
がぎぐげご
ざじずぜぞ
だぢづでど
ばびぶべぼ
ぱぴぷぺぽ
ＡＢＣＤＥ
ＦＧＨＩＪ
ＫＬＭＮＯ
ＰＱＲＳＴ
ＵＶＷＸＹ
Ｚ
１２３４５
６７８９０
記号

Weblioのサービス

「プロテオパチー」の関連用語

1
追加画像
ウィキペディア小見出し辞書
100% |||||

2
プロテオパチーのリスト
ウィキペディア小見出し辞書
56% |||||

3
播種誘発
ウィキペディア小見出し辞書
50% |||||

4
病態生理
ウィキペディア小見出し辞書
50% |||||

5
タンパク質の誤ったフォールディングと神経変性疾患
ウィキペディア小見出し辞書
14% |||||

6
多量体化と凝集
ウィキペディア小見出し辞書
10% |||||

7
フォールディング
百科事典
4% |||||

8
アルツハイマー型認知症の生化学
百科事典
2% |||||

9
プリオン
百科事典
2% |||||

10
タウタンパク質
百科事典
2% |||||

プロテオパチーのお隣キーワード

プロテウス属

プロテウス症候群

プロテウス航空

プロテウス航空706便空中衝突事故

プロテオグリカン

プロテオバクテリア

プロテオパチー

プロテオーム

プロテオーム解析

プロテオ古細菌界

プロテクション

プロテクター

プロテクター (映画)

検索ランキング

   

 英語⇒日本語
日本語⇒英語		    


プロテオパチーのページの著作権
Weblio 辞書 情報提供元は 参加元一覧 にて確認できます。

   
ウィキペディアウィキペディア
All text is available under the terms of the GNU Free Documentation License.
この記事は、ウィキペディアのプロテオパチー (改訂履歴)の記事を複製、再配布したものにあたり、GNU Free Documentation Licenseというライセンスの下で提供されています。 Weblio辞書に掲載されているウィキペディアの記事も、全てGNU Free Documentation Licenseの元に提供されております。

©2024 GRAS Group, Inc.RSS